Core Viewpoint - The announcement highlights that the company's subsidiary, Luoyang Huizhong Veterinary Medicine Co., Ltd., has received a new veterinary drug registration certificate for "Penicillin V Potassium Soluble Powder," which is aimed at treating necrotic enteritis in chickens caused by Clostridium perfringens [1][2]. Group 1: New Veterinary Drug Information - The new veterinary drug is named "Penicillin V Potassium Soluble Powder" and is classified as a Category V drug [1]. - The main ingredient is Penicillin V Potassium, which is indicated for treating necrotic enteritis in chickens caused by Clostridium perfringens [2]. - The recommended dosage is 13.5 to 20 mg per kg of body weight for chickens, to be administered once daily for five consecutive days [1]. Group 2: Market Background and Development - The drug was developed in collaboration with Jinan Lingpai Biological Pharmaceutical Technology Co., Ltd. and has been clinically used abroad for many years, demonstrating safety and high efficacy [2]. - The prevalence of coccidiosis in chickens leads to significant economic losses in the poultry industry, and existing treatments can lead to drug resistance and are often expensive [2]. - Currently, there is no available data on the sales and market share of similar products in circulation [3]. Group 3: Regulatory and Market Impact - Before the product can be marketed, it must obtain a veterinary product approval number from the Ministry of Agriculture and Rural Affairs [4]. - The successful acquisition of the new drug certificate reflects the company's commitment to technological innovation and is expected to enhance its market competitiveness [5].

受美国关税政策影响，全球股市动荡加剧，A股、港股4月7日也出现大幅回调。4月7日，A股、港股集体下挫，其中沪指收跌7.34%，报3096.58点，超2900 股跌停。港股市场方面，恒生指数盘中一度跌超13%。虽然A股、港股受外围恐慌情绪影响出现大跌，但不少机构认为中国资产在这一轮的博弈中显示出一 定韧性，可能短期内会看到一轮风险偏好的收缩，但从中长期维度，A股估值处于历史低位，耐心资本持续流入将支撑其走出独立行情。另外，4月7日，中 央汇金公司发布公告称，充分认可当前A股配置价值，坚决维护资本市场平稳运行。 | 行情列表 | | 多股同列 | 股票开户就选东方财富证券>> | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 序 代码 | | 名称 | *● 最新 涨幅% | 涨跌 | 最高 | 最低 | 开 | | 4 NDX100 | | 纳斯达克100 | 17397.70 | -6.07 -1123.78 | 18089.25 | 17387.83 | 18022.1 | | 5 SPX | | 标普500 | 5074.08 | ...

证券代码：688526 证券简称：科前生物 公告编号：2025-006 新兽药名称：牛支原体活疫苗（HB150 株） 英文名：Mycoplasma bovis Vaccine, Live (Strain HB150) 新兽药注册证书号：（2025）新兽药证字 11 号 武汉科前生物股份有限公司 关于获批新兽药注册证书的自愿性信息披露公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依 法承担法律责任。 根据《兽药管理条例》和《兽药注册办法》规定，经中华人民共 和国农业农村部审查，批准公司申报的牛支原体活疫苗（HB150 株） 为新兽药，并核发《新兽药注册证书》，具体详情如下： 一、新兽药的基本信息 牛支原体（Mycoplasma bovis，M. bovis）是一种导致牛呼吸系 统疾病的重要病原；除肺炎外，还可导致乳腺炎、关节炎、中耳炎、 角膜结膜炎、生殖道炎症、流产与不孕等。该病在世界范围内存在， 欧洲每年约有 1/3 的犊牛肺炎是由牛支原体引起的。我国于 2008 年 首次报道肉牛的牛支原体肺炎，至今已发现在全国普遍流行，肉牛和 奶牛 ...